Bronte Capital Management Pty Ltd. Vir Biotechnology, Inc. Transaction History
Bronte Capital Management Pty Ltd.
- $1.12 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding VIR
# of Institutions
222Shares Held
85.8MCall Options Held
231KPut Options Held
132K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$170 Million1.37% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$167 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$131 Million0.0% of portfolio
-
State Street Corp Boston, MA5.09MShares$51.8 Million0.0% of portfolio
-
Baillie Gifford & CO2.38MShares$24.2 Million0.01% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $1.35B
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...